Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulzer IntraTherapeutics To Submit PMA For Renal Indication In Early 2002

This article was originally published in The Gray Sheet

Executive Summary

Sulzer Medica's IntraTherapeutics unit intends to submit a premarket approval application to FDA for use of its IntraStent DoubleStrut ParaMount XS stent delivery system in the renal artery in the first quarter of 2002.

You may also be interested in...



Medtronic Bridge X3

Renal stent system gains CE mark approval for European marketing. Indicated for the treatment of atherosclerotic disease in the renal arteries, the device has a 6 Fr crossing profile and high radial strength to withstand the elastic recoil found in renal arteries, the company claims. The stent has an unexpanded length of 17 mm and comes in diameters of 5, 6, and 7 mm. The balloon catheter used to deliver the stent comes in lengths of 75 and 120 cm. A version of the system with the same name for the biliary tract is set to be unveiled the week of June 12, according to the company

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
UsernamePublicRestriction

Register

MT014539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel